| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | CSO & EVP, Head of Research | Common Stock | 12.9K | $3.54M | $274.65 | Aug 12, 2024 | Direct |
| ALNYLAM PHARMACEUTICALS, INC. | CSO & EVP, Head of Research | Common Stock | 537 | $147K | $274.65 | Aug 12, 2024 | by Managed Account |
| Ovid Therapeutics Inc. | Director | Stock Option (Right to Buy) | 30K | Feb 22, 2024 | Direct | ||
| ALNYLAM PHARMACEUTICALS, INC. | CSO & EVP, Head of Research | Stock Option (right to buy) | 0 | Aug 12, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | Aug 12, 2024 | 10 | -$4.12M | 4 | Aug 14, 2024 | CSO & EVP, Head of Research |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | Jun 24, 2024 | 13 | -$277K | 4 | Jun 26, 2024 | CSO & EVP, Head of Research |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | Mar 20, 2024 | 0 | $0 | 3 | Mar 28, 2024 | CSO & EVP, Head of Research |
| OVID | Ovid Therapeutics Inc. | Feb 22, 2024 | 1 | $0 | 4 | Feb 26, 2024 | Director |
| OVID | Ovid Therapeutics Inc. | Feb 23, 2023 | 1 | $0 | 4 | Feb 27, 2023 | Director |
| OVID | Ovid Therapeutics Inc. | Feb 3, 2022 | 1 | $0 | 4 | Feb 4, 2022 | Director |
| OVID | Ovid Therapeutics Inc. | Oct 6, 2021 | 1 | $0 | 4 | Oct 7, 2021 | Director |
| OVID | Ovid Therapeutics Inc. | Oct 6, 2021 | 0 | $0 | 3 | Oct 7, 2021 | Director |